

Transaction Contacts



SVB Securities Serves as Joint Bookrunner for Prometheus Biosciences' (Nasdag: RXDX) \$500 Million Follow-On Offering

 Publish marketed transaction that learning Describer 7th post-time and priced Describer 8th post-close. The effective followed Prometheur's December 7th appropriate of conflict feature data from the Company's silomative colitis and Crohela disease, respectively, leading to a 1-day stock price reaction of MS 7%.

- The stock traded up 22.3%-during the marketing period and the base deal sea upsized from \$250 million to
- Wall oversubscribed from both new and existing investors.
- Dead consisted of 4.545.005 shares of common stock offered at a raidic effector origin of \$110.00 per share.
- Promethese intends to use the not proceed a from this offering, together with its existing cash, cash equivalents This is SVB Securities: 2nd backnaming offering for Prometheus and 48th backnameguity offering in 2022.